Nanjing-based biotechnology start-up BioHeng Biotech today announced that it has raised a RMB100 million (US$14.8 million) series A financing round from Decheng Capital, an early-stage life science-focused venture capital firm.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?